The aim of present work is to develop a fast disintegrating solid oral dosage form of Metoprolol succinate. The concept of fast dissolving drug delivery system emerged from the desire to provide patient with more conventional means of taking their medication. Problems associated with conventional tablets can be resolved by means of fast dissolving tablets when put on tongue these tablets disintegrate and dissolve rapidly in saliva without need of drinking water. The faster the drug disintegrates in to solution, the quicker the absorption and onset of clinical effect. Preformulation results reveal that the flow properties of the active pharmaceutical ingredient were found to be excellent as per IP limits. To perform drug-polymer compatibility FT-IR studies were carried out and observed that there was no interaction between the APl and excipients. Eight formulations were prepared with varying super disintegrating agent ratios and were found that as the level of super disintegrating agent decreased the drug release rates were found to be increased. Amongst all the formulations, formulation containing CCS (F4) as super disintegrant is fulfilling all the parameters satisfactorily. It has shown excellent in-vitro disintegration, in-vitro dissolution compared to other formulations. The prepared tablets disintegrate within few minutes without need of water; thereby enhance the absorption leading to its increased bioavailability. It was concluded that Fast Disintegrating tablets of Metoprolol can be prepared successfully as it satisfies all the criteria as a dispersible tablet and would be alternative to the currently available conventional tablets. Prepared formulations were stable during 90 days storage period at controlled 40°C and 75%RH.
In the past few decades, considerable attention has been focused on the development of new drug delivery system (NDDS). The NDDS should ideally fulfill two prerequisites. Firstly, it should deliver the drug at a rate directed by the needs of the body, over the period of treatment. Secondly, it should channel the active entity to the site of action. Conventional dosage forms including prolonged release dosage forms are unable to meet none of these. At present, no available drug delivery system behaves ideally, but sincere attempts have been made to achieve them through various novel approaches in drug delivery. The aim of present work is to develop a niosomal drug delivery system of aceclofenac. To perform drug-polymer compatibility FT-IR studies were carried out and observed that there was no interaction between the APl and excipients. 8 niosomal formulations are prepared by the thin film hydration method using the cholesterol as the phospholipid. Prepared niosomal formulations were characterized by vesicle size, shape, surface charge, entrapment efficiency, drug content and invitro drug release studies. The vesicle size, size distribution and zeta potential of the optimized formulation (F5) was found to be 65.6 nm and zeta potential was found to be -1.5mV. Size distribution curve confirms the normal size distribution of the vesicles. The % entrapment efficiency of niosomal vesicles formulations were found to be in the range of 54.18±0.59 to 92.71±0.56 and optimized formulation was found to be 92.71±0.56 and drug content of niosomes formulations (F1to F8) were determined to be in the range of 94.6 -97.8%. The pH of all topical niosomal gels were found to be in the range of 7.4±0.02 to 7.4±0.08.The best fit with higher correlation (r2> 0.99) was found with the Zero Order Release and follows Korsemeyer peppas equation for all the formulations, which means that release of Aceclofenac from the lipid bilayer vesicles were due to diffusion. The stability studies were carried out and there was no significant change found in the formulations.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.